Literature DB >> 20955355

Cohort profile: the German ClinSurv HIV project--a multicentre open clinical cohort study supplementing national HIV surveillance.

J Bätzing-Feigenbaum1, C Kollan, A Kühne, D Matysiak-Klose, B Gunsenheimer-Bartmeyer, O Hamouda.   

Abstract

BACKGROUND: New forms of HIV/AIDS therapy require new surveillance instruments to meet shifting public health demands. The Clinical Surveillance of HIV Disease (ClinSurv HIV) project was established in 1999 as a collaboration between major HIV treatment centres in Germany and the Robert Koch Institute (RKI). The project contributes to national HIV surveillance and focuses on the changing epidemiology of HIV/AIDS after the introduction of new therapies in 1995.
METHODS: ClinSurv HIV is designed as an open multicentre observational cohort study of HIV-infected patients. Anonymized data on diagnoses, treatment and laboratory parameters are collected in a standardized format. Data are currently sampled biannually via 11 centres specializing in HIV diagnosis and care within the legal framework of the German Protection against Infection Act [Infektionsschutzgesetz (IfSG)].
RESULTS: A total of 14874 patients were enrolled in the study by 30 June 2009. Of these, 10221 patients (68.7%) were enrolled after 1 January 1999 and 6006 patients (40.4%) were known to have been diagnosed as positive for HIV before 1999. Evaluation indicators, such as the number of newly enrolled patients per half-year period, loss to follow-up, completeness of data per case, availability of data per possible clinical contact, and internal quality control parameters, show a very stable evolution in the cohort, which although open, can be observed. Comparison with the national HIV surveillance data suggests a high degree of representativeness according to major demographic variables.
CONCLUSION: Bearing in mind the obvious strengths and weaknesses discussed, the German ClinSurv HIV cohort provides a broad range of research opportunities in the field of HIV/AIDS both within Germany and in international collaborative research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955355     DOI: 10.1111/j.1468-1293.2010.00879.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  15 in total

1.  HIV-prevalence in tuberculosis patients in Germany, 2002-2009: an estimation based on HIV and tuberculosis surveillance data.

Authors:  Lena Fiebig; Christian Kollan; Barbara Hauer; Barbara Gunsenheimer-Bartmeyer; Matthias An der Heiden; Osamah Hamouda; Walter Haas
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

2.  Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.

Authors:  Matthias Stoll; Christian Kollan; Frank Bergmann; Johannes Bogner; Gerd Faetkenheuer; Carlos Fritzsche; Kirsten Hoeper; Heinz-August Horst; Jan van Lunzen; Andreas Plettenberg; Stefan Reuter; Jürgen Rockstroh; Hans-Jürgen Stellbrink; Osamah Hamouda; Barbara Bartmeyer
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

3.  Estimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in Germany.

Authors:  Daniel Schmidt; Christian Kollan; Gerd Fätkenheuer; Eugen Schülter; Hans-Jürgen Stellbrink; Christian Noah; Björn-Erik Ole Jensen; Matthias Stoll; Johannes R Bogner; Josef Eberle; Karolin Meixenberger; Claudia Kücherer; Osamah Hamouda; Barbara Bartmeyer
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

4.  From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany.

Authors:  Daniel Schmidt; Christian Kollan; Matthias Stoll; Hans-Jürgen Stellbrink; Andreas Plettenberg; Gerd Fätkenheuer; Frank Bergmann; Johannes R Bogner; Jan van Lunzen; Jürgen Rockstroh; Stefan Esser; Björn-Erik Ole Jensen; Heinz-August Horst; Carlos Fritzsche; Andrea Kühne; Matthias an der Heiden; Osamah Hamouda; Barbara Bartmeyer
Journal:  BMC Public Health       Date:  2015-03-17       Impact factor: 3.295

5.  CD4-cell counts and presence of AIDS in HIV-positive patients entering specialized care-a comparison of migrant groups in the German ClinSurv HIV Cohort Study, 1999-2013.

Authors:  Nadine Zeitlmann; Barbara Gunsenheimer-Bartmeyer; Claudia Santos-Hövener; Christian Kollan; Matthias An der Heiden
Journal:  BMC Infect Dis       Date:  2016-12-07       Impact factor: 3.090

6.  Surveillance of recent HIV infections among newly diagnosed HIV cases in Germany between 2008 and 2014.

Authors:  Alexandra Hofmann; Andrea Hauser; Ruth Zimmermann; Claudia Santos-Hövener; Jörg Bätzing-Feigenbaum; Stephan Wildner; Claudia Kücherer; Norbert Bannert; Osamah Hamouda; Viviane Bremer; Barbara Bartmeyer
Journal:  BMC Infect Dis       Date:  2017-07-11       Impact factor: 3.090

7.  Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.

Authors:  Basel Karo; Gérard Krause; Stefanie Castell; Christian Kollan; Osamah Hamouda; Walter Haas
Journal:  BMC Infect Dis       Date:  2017-07-25       Impact factor: 3.090

8.  Patient preferences for HIV/AIDS therapy - a discrete choice experiment.

Authors:  Axel C Mühlbacher; Matthias Stoll; Jörg Mahlich; Matthias Nübling
Journal:  Health Econ Rev       Date:  2013-05-11

9.  Towards estimation of HIV-1 date of infection: a time-continuous IgG-model shows that seroconversion does not occur at the midpoint between negative and positive tests.

Authors:  Helena Skar; Jan Albert; Thomas Leitner
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

10.  Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors.

Authors:  Basel Karo; Walter Haas; Christian Kollan; Barbara Gunsenheimer-Bartmeyer; Osamah Hamouda; Lena Fiebig
Journal:  BMC Infect Dis       Date:  2014-03-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.